GSK
GSK
635 hedge funds and large institutions have $13.5B invested in GSK in 2013 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 235 increasing their positions, 228 reducing their positions, and 38 closing their positions.
100% more call options, than puts
Call options by funds: $174M | Put options by funds: $87.3M
16% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 38
3% more repeat investments, than reductions
Existing positions increased: 235 | Existing positions reduced: 228
0.11% less ownership
Funds ownership: 4.49% → 4.38% (-0.11%)
1% less funds holding
Funds holding: 639 → 635 (-4)
2% less capital invested
Capital invested by funds: $13.8B → $13.5B (-$303M)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$130M |
| 2 |
EAM
Edge Asset Management
Seattle,
Washington
|
+$74M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$59.9M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$26.6M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$25.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$238M |
| 2 |
FMI
Fiduciary Management Inc
Milwaukee,
Wisconsin
|
-$153M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$64.5M |
| 4 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$58.2M |
| 5 |
Bank of New York Mellon
New York
|
-$38.9M |
GSK Hedge Fund Activity: Q3 2013 in Review
635 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q3 2013, worth a combined $13.5B — down 2.2% from $13.8B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new GSK positions and 38 closed out — a net gain of 6 holders — while 235 added to existing stakes and 228 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $130M. The largest seller was Arrowstreet Capital, cutting an estimated $238M.
- 635 institutional investors held GSK (GSK) as of Q3 2013, down from 639 in Q2 2013.
- Funds reported $13.5B of GSK stock for Q3 2013, down 2.2% quarter-over-quarter.
- 44 funds opened new GSK positions in Q3 2013 and 38 closed out, a net change of +6 holders.
- The largest GSK buyer in Q3 2013 was Renaissance Technologies, an estimated $130M added.
- The largest GSK seller in Q3 2013 was Arrowstreet Capital, an estimated $238M sold.
Based on aggregated 13F filings for Q3 2013.